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controls, model group, the drug groups were administrated
with Vit E (10mg/kg, ip.) and CAPE (3mg/kg, 6mg/kg,
12mg/kg, ip. & 12mg/kg, 24mg/kg, ig.) daily throughout
10 weeks. At the end of the experiment, GSH, SOD and MDA
levels and CAT activity of liver homogenate were quantiﬁed.
Excised liver tissue was taken to undergo HE and Van Gieson
staining.
Results: Data showed decrease in MDA level and increase
in GSH, SOD levels, and CAT activity in the CAPE
treated groups, compared with model group. There were
statistically signiﬁcant difference between CAPE (12mg/kg,
6mg/kg, via ip route) groups and model group (p < 0.05),
and the other CAPE treated groups were not. What’s more,
treatment with CAPE attenuated the inﬂammation and
ﬁbroplasias induced by CCl4, alcohol and high-lipid forage.
In conclusion, CAPE protects against CCl4, alcohol and
high-lipid forage induced oxidative stress, and enhances
antioxidant capacity. In addition, intraperitoneal injection
is the better way to produce the best pharmacodynamic
effects.
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Background: The progressing increasing of hypoxia inducible
factor-1alpha (HIF-1a) and HIF-1amRNA were found during
the malignant transformation of hepatocytes in our previous
work. In this study, the expression of hepatic HIF-1a
and level of its gene transcription were investigated in
different tissues of human hepatocellular carcinoma (HCC)
for exploring the relationship between HIF-1a expression
and HCC development.
Methods: The alterations of liver HIF-1a transcription
and expression were observed through the self-controlled
specimens from 35 human HCC patients. The expression
and cellular distribution of hepatic HIF-1a were analyzed
by immohistochemistry. The gene fragments of HIF-1amRNA
in different liver tissues were ampliﬁed by nested-PCR, and
conﬁrmed by sequencing.
Results: The positive HIF-1a was brown and granule-
like, mainly presented in cytoplasm and few in nucleus.
The incidence of HIF-1a expression was 80% (28/35) in
HCC, and 100% (35/35) in their paracancerous tissues,
respectively. The speciﬁc concentrations of total RNA were
12.4±7.3mg/mg wet liver in HCC and 53.8±52.0 mg/mg
wet liver in their paracancerous tissues (t = 3.05, P < 0.01).
The clinical pathological features of HIF-1a expression
demonstrated that no signiﬁcant correlation was found
between HIF-1a and tumor numbers, differentiation degree
or positive-HBsAg except of tumor size.
Conclusion: Hepatic HIF-1a expression is associated with
development and prognosis of HCC, and should be an
attractive molecular-target for HCC therapy.
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Background: Hepatocellular carcinoma (HCC) prognosis is
poor and early diagnosis is of the utmost importance.
The objective of this study was to investigate the
dynamic expression of glypican-3 (GPC-3) and its gene in
hepatocarcinogenesis, the relationship of its expression with
HBV infection, and diagnostic values for HCC.
Methods: The characteristics of GPC-3 expression were
observed by rat hepatoma models. Liver GPC-3 Expression
was analyzed by immunohisto-chemistry or Western
blotting. Hepatic GPC-3 mRNAs were extracted and
ampliﬁed by using a nested polymerase chain reaction (PCR)
or real-time PCR assay. The ampliﬁed fragments of GPC-3
gene were conﬁrmed by DNA sequencing. The level of serum
GPC-3 in patients with liver diseases was quantitatively
detected by an ELISA method.
Results: The dynamic alteration of GPC-3 was conﬁrmed by
hepatoma models with brown granule-like staining localized
in membrane and cytoplasm in morphological stages of
granule-like degeneration, atypical hyperplasia and cancer
formation. Of self-control human HCC tissues, the incidence
of GPC-3 was 80.6% in HCC, 41.7% in their surrounding,
and none in distant group (c2 = 11.445, P < 0.000) with no
signiﬁcant relationship between GPC-3 and differentiation
grade or tumor number except of tumor size (Z = 2.941,
P = 0.003); and the features of circulating GPC-3 was
detected in only HCC patients (52.8%) without signiﬁcant
different between GPC-3 and sex, age, AFP, tumor number,
Child-pugh classiﬁcation or extrahepatic metastasis except
of size (c2 = 6.318, P = 0.012) and HBV infection (c2 = 23.362,
P < 0.000). Combined analysis of GPC-3 and AFP levels could
rise up to 87% for HCC diagnosis.
Conclusions: Abnormal expression of hepatic and circulating
GPC-3 may be associated closely with occurrence of HCC
and could be a useful speciﬁc molecular marker for HCC
diagnosis.
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Background: Chronic hepatitis B (CHB) is a severe
liver disease and can progressively develop hepatic
ﬁbrosis. Notably, high levels of tissue inhibitor of
metalloproteinases-1 (TIMP-1) expression are observed
in patients with liver ﬁbrosis. However, the potential
relationship between the levels of serum TIMP-1, hepatic
TIMP-1, and the degrees of hepatic ﬁbrosis in patients with
CHB has not yet been illustrated. This study aimed at
investigating the relationship between TIMP-1 expression
and liver ﬁbrosis severity in patients with CHB.
Methods: In the present study, a total of 159 CHB
with varying degrees of liver ﬁbrosis were recruited and
subjected to liver biopsy for the analysis of their liver
ﬁbrotic stages and inﬂammatory activities. The levels of
TIMP-1 expression in the liver tissues and serum TIMP-1 in
those patients were determined by immunohistochemistry
and enzyme-linked immunoabsorbent assay (ELISA),
respectively.
Results: Our results indicated that the concentrations of
serum TIMP were positively correlated with the levels
of TIMP-1 expression in the liver tissues (R = 0.9521) and
the degrees of liver ﬁbrosis (0.704) in CHB patients
with inﬂammation at grade 2. More importantly, the
concentrations of serum TIMP-1 were independent of the
degrees of inﬂammation in those patients.
Conclusion: Our ﬁndings suggest that the TIMP-1 may be a
valuable biomarker, and that the detection of serum TIMP-1
concentrations may be a safe and cost-effective measure
for the evaluation of liver ﬁbrosis at least in CHB patients.
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Background and Aims: Until now, it is still not very clear
what impact the progression and result in fatal outcomes
of acute-on-chronic hepatitis B liver failure (HB-ACLF).
Model for end-stage liver disease (MELD) scores system is
an internationally recognized to predict the pathogenetic
condition of the end-stage liver disease. The study is to
investigate the dynamics and clinical signiﬁcances of serum
HBV DNA levels and MELD scores in the terminal phase of
HB-ACLF.
Methods: 106 fatal patients with HB-ACLF were enrolled,
who had never accepted antiviral therapy or liver
transplantation. At three phases of 29 90 d, 8 28 d and
1 7 d before death, they were detected serum HBV DNA
levels by Realtime-PCR in order meanwhile MELD scores
were calculated.
Results: In 35 patients with HBeAg positive, HBV DNA levels
were 6.16±1.59 log10, 5.63±1.52 log10 and 5.12±2.13
log10 copies/ml while MELD scores were 19.03±7.51,
24.79±6.40 and 33.06±7.64 respectively. In 71 patients with
anti-HBe positive, HBV DNA levels were 4.63±1.82 log10,
5.77±1.74 log10 and 4.69±1.68 log10 copies/ml while MELD
scores were 24.01±6.32, 28.34±7.77 and 33.25±10.13 in
sequence. HBV DNA levels of HBeAg positive group were
signiﬁcantly higher than that of anti-HBe positive group at
the phase of 29 90 d (P < 0.05). But in the same group,
HBV DNA levels were no signiﬁcant difference among
three phases, regardless of HBVe system status. With the
exacerbation of the ill, MELD scores increased steadily and
signiﬁcant difference was found in all patients (P < 0.05).
Conclusions: To initiate HB-ACLF occurrence, HBeAg
positive patients need higher serum HBV DNA levels than
that of anti-HBe positive ones. Regardless of HBVe system
status, sustained high HBV DNA levels may promote the
disease worsened and be fatal to patients.
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Background: To compare the clinical features of
spontaneous decrease of HBV DNA level between Hepatitis B
e antigen (HBeAg)-positive and HBeAg-negative chronic
hepatitis B patients (CHB).
Methods: Dynamic change of HBV DNA level was observed
for 12 weeks in 315 cases with admission HBV DNA level
above 10,000 copies/mL. All patients had never been
treated with antiviral or immunoregulatory drugs during
this period. In the ﬁrst observation week, HBV DNA, HBeAg,
ALT, AST, total bilirubin (TBIL), prothrombin time (PT)
were detected. HBV DNA was redetected at the end of
observation period. These cases were divided into subgroups
according to HBeAg and HBV DNA decrease (HBeAg-negative
group, HBeAg-positive group, and each was subgrouped into
decreased subgroup and non-decreased subgroup).
Results: Among the 315 CHB patients, 171 patients (54.3%)
underwent spontaneous decrease of HBV DNA level within
12 weeks. 83 (55.0%) of 151 HBeAg-positive patients
underwent spontaneous decrease of HBV DNA level, while
88 (53.7%) of 164 HBeAg-negative patients underwent that.
The difference between the above two groups was not
signiﬁcant (c2 = 0.054, P = 0.816). Among HBeAg-positive
patients, AST, TBIL, PT were higher in patients with
spontaneous decrease of HBV DNA level than in those
without (t = 3.485- 4.156, P = 0.000 0.001). Among HBeAg-
negative patients, HBV DNA, ALT, AST, TBIL, PT were higher
in patients with spontaneous decrease of HBV DNA level than
in those withoutv (t = 5.224 2.476, P = 0.000 0.014).
Conclusion: Half of the observed CHB patients underwent
spontaneous decrease of HBV DNA level, and the worse the
hepatic function was, the higher incidence of spontaneous
decrease of HBV DNA level would be whenever HBeAg were
positive or not.
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Background: The time delay mathematical models are
often used to describe the process of HBV infection
and treatment. Based on the basic virus infection model
introduced by Nowak et al. and Park Soo’s data of adefovir,
we set up a time delay model to simulate the dynamic
behavior of free viral, here the time delay stands for the
time between viral entry into a target cell and production
of new virus particles.
Methods: The model is described by three variables: x,
y, v represent the numbers of susceptible cells, infected
cells, and free virus. The model include 12 parameters:
l, d, c, h, b, a, n, k, u, xmax, t, e-mt, where c is the
maximum proliferation rate of target cells, xmax is the
x population density at which proliferation shuts off, h and n
represent the efﬁcacy of the therapy, e-mt accounts for
cells that are infected at time t but die before becoming
productively infected t time units later, the meanings of
l, d, b, a, k, u are the same as those given in Nowak’s
model. During treatment, we chose { l, d, c, h, b, a, n, k,
u, xmax, t, e-mt} = {2.525×102, 3.79e-004, 3×10 6, 0.5,
40, 1.644e-003, 0.9999, 0.0749, 0.1679, 6.6623e+005, 1.8,
e-0.00002×1.8}.
Results: The simulation data of the free viral in our model
is consistent with the clinical data perfectly.
Conclusion: The result shows that our time delay anti-
HBV model may be used as a reference for comparing
the efﬁciency of different drugs, and other HBV infection
models.
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Background: Asymptomatic CK elevations were observed in
patients who received the telbivudine treatment. This study
is to analyze the factors related to this phenomenon.
